CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)
$92.00$81.00
The CJC-1295 (Mod GRF 1-29), Ipamorelin, and GHRP-2 blend is a research compound containing three synthetic peptides that are being studied for their potential to stimulate the release of growth hormone. CJC-1295 (Mod GRF 1-29) acts as an agonist for the Growth Hormone-Releasing Hormone (GHRH) receptors, while Ipamorelin and GHRP-2 are agonists for the ghrelin receptors. While research on the combined blend is limited, studies on the individual peptides suggest a synergistic effect, as they act on different pathways to potentially achieve a more significant release of growth hormone.
Product Specifications
Specification | Details |
SKU | P-CJCIPAMGHR2-9 |
Purity | >99% |
Form | Lyophilized Powder |
Size | 9 mg (3 mg of each peptide) |
Contents | CJC-1295 (Mod GRF 1-29), Ipamorelin, GHRP-2 |
Pricing
Free shipping on all orders over $200!
Quantity | Discount | Price (USD) |
5 - 8 | 5% | $76.95 |
9+ | 10% | $72.90 |
Chemical Makeup
Peptide | Molecular Formula | Molecular Weight | Other Known Titles |
CJC-1295 (Mod GRF 1-29) | C152H252N44O42 | 3367.9 g/mol | Growth Hormone-Releasing Hormone (GHRH) agonist |
Ipamorelin | C38H49N9O5 | 711.9 g/mol | Ipamorelin Acetate, IPA |
GHRP-2 | C45H55N9O6 | 817.9 g/mol | Pralmorelin |
Research and Clinical Studies
Blend and Growth Hormone Deficiencies
In clinical trials, peptides like CJC-1295, Ipamorelin, and GHRP-2 have been observed to increase growth hormone secretion in subjects with growth hormone deficiency. The exact mechanism—whether by stimulating the pituitary gland directly or acting on the hypothalamus—is still under investigation. A study on six subjects with growth failure showed a gradual rise in growth hormone concentration, suggesting that these peptides were well-tolerated and could stimulate GH secretion.
Blend and Food Intake
Because Ipamorelin and GHRP-2 act on the ghrelin receptors (also known as the "hunger hormone" receptors), they may influence appetite. A study with GHRP-2 showed that subjects ate approximately 36% more than the control group. Similarly, Ipamorelin is being researched for its potential to increase food consumption, which may lead to weight gain. CJC-1295, however, has not been suggested to affect appetite.
Blend and Bone Mass
By potentially increasing growth hormone synthesis, this peptide blend may have the potential to upregulate bone mineral density (BMD). A study on Ipamorelin in murine models suggested that it may have contributed to a potential weight gain and an increase in bone mineral content. The increase was believed to be a result of improved bone growth leading to expanded bone dimensions, with volumetric BMD remaining consistent.
Blend and Muscle Mass
Research suggests that this blend, specifically CJC-1295, may have favorable actions on lean mass. In murine models with a GHRH gene deletion, CJC-1295 appeared to help retain lean weight and length, unlike control groups. It also appeared to increase the number of somatotroph cells, which are responsible for producing growth hormone. Ipamorelin has also been proposed to increase lean mass by creating a positive nitrogen balance.
Disclaimer: This peptide blend is for research and laboratory purposes only.
